Provectus Biopharmaceuticals, Inc.
PVCT
$0.07
$0.006.82%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -91.26% | -45.54% | -51.60% | -32.72% | 11.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -91.26% | -45.54% | -51.60% | -32.72% | 11.33% |
| Cost of Revenue | -2.65% | -7.36% | 16.31% | 25.18% | 4.83% |
| Gross Profit | -48.86% | -10.24% | -61.38% | -62.23% | -1.37% |
| SG&A Expenses | -5.22% | 34.91% | 304.63% | 304.00% | 284.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.76% | 16.17% | 126.66% | 128.26% | 105.94% |
| Operating Income | -7.16% | -25.83% | -186.07% | -181.73% | -133.25% |
| Income Before Tax | -4.15% | -15.60% | -122.35% | -130.29% | -95.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.15% | -15.60% | -122.35% | -130.29% | -95.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 23.87% | 151.01% | -- | -- | -- |
| Net Income | -3.96% | -14.76% | -119.02% | -127.10% | -93.23% |
| EBIT | -7.16% | -25.83% | -186.07% | -181.73% | -133.25% |
| EBITDA | -7.24% | -26.01% | -187.16% | -182.77% | -134.00% |
| EPS Basic | -4.72% | -15.18% | -118.06% | -127.27% | -92.42% |
| Normalized Basic EPS | -5.41% | -22.58% | -161.11% | -158.82% | -124.24% |
| EPS Diluted | -4.72% | -15.18% | -118.06% | -127.27% | -92.42% |
| Normalized Diluted EPS | -5.41% | -22.58% | -161.11% | -158.82% | -124.24% |
| Average Basic Shares Outstanding | 0.07% | 0.11% | 0.16% | 0.16% | 0.12% |
| Average Diluted Shares Outstanding | 0.07% | 0.11% | 0.16% | 0.16% | 0.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |